- Merck & Exelixis collaborate to evaluate Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma.
Mon Oct 14 13:01:46 -0000 2024 UTC– Merck & Co., Inc. announced a collaboration with Exelixis to study Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma. For more details, visit the company’s website.
Recently, Merck in New Jersey announced FDA approval for KEYTRUDA plus chemotherapy for mesothelioma treatment.
In the U.S., KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business